IR CD-LD

DRUG3 trials

Sponsors

Impax Laboratories, LLC

Conditions

Parkinson's DiseaseParkinson's Disease (Disorder)

Phase 2

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

CompletedNCT00869791

Impax Laboratories, LLCParkinson's Disease

Start: 2008-11-30End: 2009-06-30Updated: 2019-11-08

Phase 3

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

CompletedNCT00974974

Impax Laboratories, LLCParkinson's Disease

Start: 2009-09-30End: 2011-03-31Updated: 2020-08-11

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

CompletedNCT03670953

Impax Laboratories, LLCParkinson's Disease (Disorder)

Start: 2018-11-06End: 2021-06-15Updated: 2023-02-09

Related Papers

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease

JAMA Neurology2023-08-1433 citations

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations

Parkinson s Disease2018-10-224 citations

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

2013-02-26131 citations